Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of a Directorate Change rather than a financial results announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance updates.
Material Changes
The primary material change disclosed is the appointment of Mr. Hans Wijers as a Non-Executive Director, effective April 1, 2013. This follows a prior announcement made on January 24, 2013. The Company confirms no further disclosures are required under Listing Rule 9.6.13R.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly a confirmation of the directorate appointment.
Investor Verification Checklist
- Verify the effective date of Mr. Hans Wijers' appointment as Non-Executive Director (April 1, 2013).
- Confirm that no additional disclosures are pending under Listing Rule 9.6.13R.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for financial metrics.